Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus

Oesophageal Carcinoma Clinical Trial

Official title:
Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized Squamous Cell Carcinoma of the Oesophagus

Status Completed

Clinical Trial Summary

This is a study to investigate the efficacy and safety of epirubicin, cisplatin and capecitabine (ECX) as neoadjuvant therapy prior to radical chemoradiotherapy using capecitabine and cisplatin as radio-sensitisers in patients with newly diagnosed localized squamous cell carcinoma of the oesophagus.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00220129
Study type	Interventional
Source	Royal Marsden NHS Foundation Trust
Contact
Status	Completed
Phase	Phase 2
Start date	November 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04027543` - Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）
Recruiting	`NCT05714553` - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours	Phase 1/Phase 2
Active, not recruiting	`NCT03835663` - The Bacterial Composition of the Stomach in Reflux Disease
Active, not recruiting	`NCT03246516` - Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers	N/A
Terminated	`NCT02999893` - A Study of APR-246 in Oesophageal Cancer	Phase 1/Phase 2